Scarica l'app Stockscreener
1.415
0.35%
-0.005
Precedente Chiudi:
$1.42
Aprire:
$1.38
Volume 24 ore:
3.46M
Relative Volume:
0.20
Capitalizzazione di mercato:
$210.99M
Reddito:
$424.90K
Utile/perdita netta:
$-94.02M
Rapporto P/E:
-0.5696
EPS:
-2.4842
Flusso di cassa netto:
$-51.25M
1 W Prestazione:
-11.01%
1M Prestazione:
+82.18%
6M Prestazione:
+139.83%
1 anno Prestazione:
-23.92%
Intervallo 1D:
$1.37
$1.52
Intervallo di 1 settimana:
$1.30
$1.63
Portata 52W:
$0.1611
$3.39
Outlook Therapeutics Inc Stock (OTLK) Company Profile
Nome
Outlook Therapeutics Inc
Settore
Industria
Telefono
(609) 619-3990
Indirizzo
111 S. WOOD AVENUE, ISELIN, NJ
Compare OTLK vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
OTLK
Outlook Therapeutics Inc
|
1.42 | 215.45M | 424.90K | -94.02M | -51.25M | -2.4842 |
VRTX
Vertex Pharmaceuticals Inc
|
524.75 | 134.02B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
672.67 | 68.59B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
920.36 | 58.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
319.89 | 41.76B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
191.85 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
Outlook Therapeutics Inc Stock (OTLK) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-29 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2025-08-28 | Downgrade | Guggenheim | Buy → Neutral |
| 2024-12-02 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2024-03-27 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2024-02-15 | Aggiornamento | Chardan Capital Markets | Neutral → Buy |
| 2024-01-25 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-12-27 | Aggiornamento | CapitalOne | Equal Weight → Overweight |
| 2023-08-31 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2023-08-31 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2023-08-30 | Downgrade | BTIG Research | Buy → Neutral |
| 2023-08-30 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2023-08-30 | Downgrade | CapitalOne | Overweight → Equal Weight |
| 2023-08-30 | Downgrade | Guggenheim | Buy → Neutral |
| 2023-07-13 | Iniziato | CapitalOne | Overweight |
| 2023-04-03 | Iniziato | Guggenheim | Buy |
| 2023-02-06 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-10-31 | Iniziato | BTIG Research | Buy |
| 2022-09-13 | Iniziato | Chardan Capital Markets | Buy |
| 2019-09-11 | Iniziato | Ladenburg Thalmann | Buy |
| 2019-05-16 | Iniziato | Oppenheimer | Outperform |
| 2019-04-22 | Iniziato | Ascendiant Capital Markets | Buy |
Mostra tutto
Outlook Therapeutics Inc Borsa (OTLK) Ultime notizie
Outlook Therapeutics(OTLK) Stock Options Chain | Quotes & News - Moomoo
Outlook Therapeutics files dispute resolution request with FDA - Investing.com
Enterprise value to revenue forward of Outlook Therapeutics, Inc. – NASDAQ:OTLK - TradingView
Why Is OTLK Stock Falling Today? - Stocktwits
OTLK Stock Soars 28% After FDA Sets July Date For Lytenava Decision - Stocktwits
Outlook Therapeutics Stock (OTLK) Opinions on FDA Review for Lytenava - Quiver Quantitative
Outlook Therapeutics Regains Nasdaq Compliance - marketscreener.com
symbol__ Stock Quote Price and Forecast - CNN
Outlook Therapeutics Regains Nasdaq Minimum Bid Compliance - The Globe and Mail
OTLKOutlook Therapeutics Inc Latest SEC Filings - Finviz
Outlook Therapeutics (OTLK) Regains Compliance with Nasdaq Minimum Bid Price Requirement – 8-K Filing June 2026 – Minichart - Minichart
Outlook Therapeutics Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Outlook Therapeutics (OTLK) restores Nasdaq minimum bid compliance, delisting threat closed - Stock Titan
OTLK Stock Climbs As FDA Fast-Tracks Lytenava Decision - StocksToTrade
Enterprise value to EBITDA forward of Outlook Therapeutics, Inc. – NASDAQ:OTLK - TradingView
Outlook Therapeutics, Inc. Actuals & Estimates (NASDAQ:OTLK) - TradingView
OTLK stock up 35% as FDA accepts resubmitted eye drug BLA for review - MSN
Outlook Therapeutics, Inc. Actuals & Estimates (FWB:41O) - TradingView
Enterprise value to revenue forward of Outlook Therapeutics, Inc. – MUN:41O - TradingView
Price to sales forward of Outlook Therapeutics, Inc. – NASDAQ:OTLK - TradingView
Price to earnings forward of Outlook Therapeutics, Inc. – NASDAQ:OTLK - TradingView
Price to earnings forward of Outlook Therapeutics, Inc. – MUN:41O - TradingView
Price to sales forward of Outlook Therapeutics, Inc. – MUN:41O - TradingView
Enterprise value to EBIT forward of Outlook Therapeutics, Inc. – NASDAQ:OTLK - TradingView
OTLK Forecast — Price Target — Prediction for 2027 - TradingView
41O Forecast — Price Target — Prediction for 2027 - TradingView
Outlook Therapeutics Inc (OTLK) Valuation: PE, PB & Fair Value Analysis - TradingKey
Outlook Therapeutics Inc (OTLK) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Price to book forward of Outlook Therapeutics, Inc. – MUN:41O - TradingView
OTLK stock soars 28% after FDA sets July date for Lytenava decision - MSN
OTLK Stock Surges On FDA Lytenava Application Resubmission After Successful Appeal - Stocktwits
Outlook Therapeutics StockWeekly review and sector context for biotech eye drug maker - AD HOC NEWS
Outlook Therapeutics Inc (OTLK) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
One Month, One Drug, One Verdict: Outlook Therapeutics' Lytenava Awaits FDA's Answer on July 29 - AD HOC NEWS
Outlook Therapeutics Heads Into Another FDA PDUFA Decision For Lytenava (NASDAQ:OTLK) - Seeking Alpha
Outlook Therapeutics Secures FDA Class-1 Review for Lytenava, Yet Cash Crunch and European Slowdown - AD HOC NEWS
Outlook Therapeutics’ Lytenava Nears FDA Verdict as Shares Skyrocket — But RSI Flashes Caution - AD HOC NEWS
Outlook Therapeutics Inc (OTLK) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Outlook Therapeutics Inc (OTLK) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
FDA accepts Outlook Therapeutics' resubmitted BLA for ONS-5010 (LYTENAVA) - Ophthalmology Times
OTLK Stock Up 35% as FDA Accepts Resubmitted Eye Drug BLA for Review - The Globe and Mail
Outlook Therapeutics Eye Drug Review Returns To FDA — AgainOutlook Therapeutics (NASDAQ:OTLK) - Benzinga
FDA accepts resubmitted BLA from Outlook Therapeutics - The Pharma Letter
Outlook Therapeutics (OTLK) Gains FDA Acknowledgment for BLA Res - GuruFocus
Outlook Therapeutics (OTLK) Stock After FDA Review Win Is The Valuation Case Already Priced In - Yahoo Finance
Outlook Therapeutics Stock Jumps as FDA Accepts Lytenava BLA, July Decision Looms - TechStock²
Outlook Therapeutics Inc Azioni (OTLK) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Outlook Therapeutics Inc Azioni (OTLK) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Sukhtian Ghiath M. | Director |
May 28 '26 |
Buy |
0.59 |
8,539,709 |
5,000,000 |
22,092,068 |
| Sukhtian Faisal Ghiath | Director |
May 27 '26 |
Buy |
0.41 |
122,174 |
50,006 |
125,574 |
| Haddadin Yezan Munther | Director |
May 26 '26 |
Buy |
0.44 |
34,000 |
14,960 |
37,167 |
| THURMAN RANDY H | Director |
May 26 '26 |
Buy |
0.43 |
5,000 |
2,145 |
5,593 |
| HILZINGER KURT J | Director |
May 26 '26 |
Buy |
0.44 |
400,000 |
176,520 |
423,655 |
1.67%
3.59%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):